[
1. CDC. Bigest Threats and Data 2019 AR Threats Report. 2019 [cited 2020]; Available from: https://www.cdc.gov/drugresistance/biggest-threats.html#cdiff.
]Search in Google Scholar
[
2. Drekonja DM, Butler M, MacDonald R, Bliss D, Filice GA, Rector TS, et al. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann Intern Med. 2011 Dec;155(12):839–47.10.7326/0003-4819-155-12-201112200-0000722184691
]Search in Google Scholar
[
3. Nelson RL, Malakun R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev. 2011;(9).10.1002/14651858.CD004610.pub421901692
]Search in Google Scholar
[
4. Sartelli M, Di Bella S, McFarland L V, Khanna S, Furuya-Kanamori L, Abuzeid N, et al. 2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World J Emerg Surg. 2019;14:8.10.1186/s13017-019-0228-3639402630858872
]Search in Google Scholar
[
5. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013 Apr;108(4):478–98.10.1038/ajg.2013.423439232
]Search in Google Scholar
[
6. Dumitru IM, Dumitru E, Cernat RC, Petcu AE, Ilie Șerban C, Rugină S. Clostridium difficile colitis – a serious current problem. BMC Infect Dis. 2013;13(1):O20.10.1186/1471-2334-13-S1-O20
]Search in Google Scholar
[
7. Crawford T, Huesgen E, Danziger L. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. Am J Heal Pharm AJHP Off J Am Soc Heal Pharm. 2012 Jun;69(11):933–43.10.2146/ajhp11037122610025
]Search in Google Scholar
[
8. Cornely OA. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? Clin Microbiol Infect. 2012;18:28–35.
]Search in Google Scholar
[
9. Dumitru IM, Dumitru E, Rugina S, Tuta LA. Toxic Megacolon - A Three Case Presentation. Vol. 3, Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures). 2017. p. 39–44.10.1515/jccm-2017-0008576989029967870
]Search in Google Scholar
[
10. Dumitru IM, Dumitru E, Alexandrescu L, Hangan A, Rugina S, Lilios G. Human Microbiome, Clostridium difficile and health. J Environ Prot Ecol. 2015;16(4):1598–602.
]Search in Google Scholar
[
11. Burke KE, Lamont JT. Fecal transplantation for recurrent Clostridium difficile infection in older adults: a review. J Am Geriatr Soc. 2013 Aug;61(8):1394–8.10.1111/jgs.1237823869970
]Search in Google Scholar
[
12. Dumitru IM, Dumitru E, Resul G, Curtali L, Paris S, Rugina S. Concomitant CMV and Clostridium difficile colitis in an immunocompetent patient treated with Ganciclovir and fecal transplantation. Vol. 23, Journal of gastrointestinal and liver diseases : JGLD. Romania; 2014. p. 221–2.10.15403/jgld-1286
]Search in Google Scholar
[
13. Vigvári S, Nemes Z, Vincze Á, Solt J, Sipos D, Feiszt Z, et al. Experience with fecal microbiota transplantation in the treatment of Clostridium difficile infection. Orv Hetil. 2014;155(44):1758–62.10.1556/OH.2014.3002025344853
]Search in Google Scholar
[
14. Khan MA, Sofi AA, Ahmad U, Alaradi O, Khan AR, Hammad T, et al. Efficacy and safety of, and patient satisfaction with, colonoscopic-administered fecal microbiota transplantation in relapsing and refractory community- and hospital-acquired Clostridium difficile infection. Can J Gastroenterol Hepatol. 2014 Sep;28(8):434–8.10.1155/2014/695029421023425014180
]Search in Google Scholar
[
15. Institute Predictive Presonalised Medicine. Fecal Transplantation. [cited 2020]; Available from: https://www.ippmclinic.com/en/fecal-transplantation.
]Search in Google Scholar
[
16. Wang J-W, Kuo C-H, Kuo F-C, Wang Y-K, Hsu W-H, Yu F-J, et al. Fecal microbiota transplantation: Review and update. J Formos Med Assoc. 2019 Mar;118 Suppl 1:S23–31.10.1016/j.jfma.2018.08.01130181015
]Search in Google Scholar
